| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f6be7b5f316f050e9151b3afd8936f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-582
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2220-80 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-291
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3251
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3219 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D15-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-32 |
| filingDate |
2014-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17b13d5d1cd05293e4c4b7752f0ec556
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b77a1da6f7c4125d60835b5acc9c63e3 |
| publicationDate |
2016-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160029840-A |
| titleOfInvention |
Affinity chromatography matrix |
| abstract |
The present invention relates to polymeric particles in which at least one oligosaccharide corresponding to the A-type blood epitope and / or the B-type blood epitope is grafted through the spacer, characterized in that the oligosaccharide density is comprised between 0.2 and 0.7 mg / To an affinity chromatography matrix as a gel. The present invention also relates to the use of such a matrix for the production of a concentrate of immunoglobulin for therapeutic use. |
| priorityDate |
2013-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |